Drug Information Related to Paroxetine Mesylate
Back
01. FDA GIVES TENTATIVE APPROVAL OF STAVZOR. - Free Online Library
Noven Pharmaceuticals, Inc. (NASDAQ:NOVN), Miami, Fla., announced
that the U.S. Food and Drug Administration (FDA) has issued a tentative
approval letter related to the New Drug Application (NDA) for Stavzor
(valproic acid delayed release capsules) in 125mg, 250m...
02. Noven to Present at Lehman Brothers Global Healthcare Conference ......
MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced
that Jeffrey F. Eisenberg, its Executive Vice President and Interim
Chief Executive Officer, is scheduled to provide an update on
Noven's business and prospects at the Lehman Brothers 11th Annual
...
03. Noven to Present at Raymond James Institutional Investors Conference ....
MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced
that Jeffrey F. Eisenberg, its Executive Vice President and Interim
Chief Executive Officer, is scheduled to provide an update on
Noven's business and prospects at the Raymond James 29th Annual
I...
04. Noven Announces Share Repurchase Program. - Free Online Library
MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced
that its Board of Directors has approved a share repurchase program
authorizing the company to repurchase up to $25 million of the
company's common stock. The repurchase program is effective
imme...
05. FDA proposes new warnings about suicide risks associated with ...
FDA has proposed that makers of all antidepressant medications
update the existing black box warning on their products' labeling
to include warnings about increased risks of suicidal thinking and
behavior, known as suicidality, in young adults ages 18 to 24 durin...
06. Register.com to Close Offer for Virtual Internet; Conference Call to ....
Business Editors NEW YORK--(BUSINESS WIRE)--March 12, 2002 Register.com (Nasdaq:RCOM RCOM - En Route Communications), a leading provider of global domain name registration and Internet services, today notified shareholders of Virtual Internet plc, a leading provide...
07. Contraindications and warnings August--2007. - Free Online Library...
FDA listed the following drugs and drug products as having had
modifications to the Contraindications and/or Warnings/Boxed Warnings
sections. For additional information or to read the full labeling of the
drug products, visit: httg://www.fda.gov/medwatch/
Act...
08. Noven Announces 2007 Financial Results. - Free Online Library
Reports Fourth Quarter EPS of $0.04, Adjusted EPS of $0.14
MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN), a specialty
pharmaceutical company with transdermal drug delivery expertise, today
announced financial results for the quarter and year ended December...
09. Noven Announces Final FDA Approval of Stavzor(TM) for the Treatment of...
New Delayed Release Valproate Therapy in Small, Easy-to-Swallow
Soft Gel Capsule to be Available in August 2008
MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced
that the U.S. Food and Drug Administration (FDA) has approved
Stavzor[TM] (valpro...
10. Base Ten Receives Patent Office Approval for MES Internet Communicatio...
TRENTON, N.J.--(BUSINESS WIRE)--July 13, 1998--Two Other MES MES - Main Engine StartMES - Malaysian Endodontic SocietyMES - Management Engineering SquadronMES - Manawatu Evening Standard (New Zealand newspaper)MES - Manufacturing Execution SystemsMES - Maple Equipment...
11. Apotex late last month announced that the FDA approved its abbreviated...
Apotex late last month announced that the FDA approved its abbreviated new drug application for paroxetine hydrochloride tablets, 10 mg, 20 mg, 30 mg and 40mg, which is the generic equivalent of GlaxoSmithKline's Paxil.
...
12. Noven to Report 2007 Fourth Quarter and Full Year Financial Results an...
SEC Comment Resolved, Noven to Maintain Current Revenue Recognition Policy
...
13. Noven Announces Results of Phase 3 Clinical Study of Once-Daily Lithiu...
MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced that a Phase 3 clinical study of its developmental once-daily lithium carbonate product ("Lithium QD") did not meet its primary endpoint with statistical significance (p-value [?] 0.15).
...
14. Noven Appoints Peter C. Brandt as President, Chief Executive Officer ....
MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that its board of directors has appointed former Pfizer, Inc. senior executive Peter C. Brandt, age 51, to the offices of President and Chief Executive Officer and to the Noven board of directors. Thes...
15. Safeguards for children taking antidepressant strengthened | FDA ......
"It now seems clear that the drugs do indeed increase the risk of suicidality in the trials, from about 2 percent to about 4 percent," says Robert Temple, M.D., director of the FDA's Office of Medical Policy. Agency experts continue to believe, however, that...
16. Noven to Present at Lehman Brothers Global Healthcare Conference ......
MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that Jeffrey F. Eisenberg, its Executive Vice President and Interim Chief Executive Officer, is scheduled to provide an update on Noven's business and prospects at the Lehman Brothers 11th Annual Globa...
17. Noven to Present at Raymond James Institutional Investors Conference ....
MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that Jeffrey F. Eisenberg, its Executive Vice President and Interim Chief Executive Officer, is scheduled to provide an update on Noven's business and prospects at the Raymond James 29th Annual Institu...
18. Noven Announces 2007 Earnings Release Date | Business Wire | Find ......
MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced its 2007 earnings release date.
...
19. Noven Amends Stockholder Rights Plan, Increasing Trigger Provision to ...
MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that its Board of Directors has approved an amendment to the company's Stockholder Rights Plan (the "Plan"). The amendment increases the stock ownership threshold that would cause rights issu...
